ecancermedicalscience

Review

Treatment of early-stage HER2 breast cancer—an evolving field

16 Apr 2015
Arlindo R Ferreira, Kamal S Saini, Otto Metzger-Filho

The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2 tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.

Related Articles

Berenice Freile, Andrés Rodriguez, Greta Catani, Marcos Bortz, Luisina Bruno, Juan M O’Connor, Federico Esteso
Amanda Acioli de Almeida Robatto, Erika Andrade Rocha, Renata Colombo Bonadio, Denis Artico Galhera, Carolina Teixeira Muratori, Admir Andre Belo Bueno, Abraão Ferreira Lopes Dornellas, Luciana Bastos Valente Alban, Carolina Ribeiro Victor, Maria Ignez Freitas Melro Braghiroli, Marília Polo Mingueti e Silva, Camila Soares Araujo, Carlos Frederico Sparapan Marques, Caio Sergio Rizkallah Nahas, Karim Yaqub Ibrahim, André Tsin Chih Chen, Paulo Marcelo Gehm Hoff, Camila Motta Venchiarutti Moniz
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston
Izaberen Sampaio Estevam, Mariana Macambira Noronha, Júlia Matos Dubanhevitz, Eric Lima Freitas Mota, Ígor Giordan Duarte Jorge, Conceição Aparecida Dornelas, Diane Isabelle Magno Cavalcante, Georgia Fiuza Alencar Araripe, Márcio Marcondes Vieira
Agodirin Olayide, Chijioke Chijindu, Mustapha Fathi, Rahman Ganiyu, Olatoke Samuel, Olaogun Julius, Akande Halima